Company
(location)

Type of
financing

Number of
shares, units
or warrants
(M)

Amount
raised
(M)

Investors; placement agents; details

Date

TOTAL: $243.93M

Ablynx NV (Ghent, Belgium)

Exercise of warrants

0.0398S

$0.18

Ablynx said an additional 39,818 common shares have been issued in exchange for €160,489 (US$176,860) as the result of the exercise of warrants

7/21/16

Adamis Pharmaceuticals Corp. (San Diego)

Private placement

1.7S

$5.00

Adamis completed a private placement pursuant to which it issued about 1.7M shares of series A-2 convertible preferred stock to a small number of institutional investors and received gross cash proceeds of about $5M

7/13/16

Apricus Biosciences Inc. (San Diego)

Private placement

2.53S

$1.00

Apricus Biosciences entered a common stock purchase agreement with Aspire Capital Fund LLC, which will complete an initial purchase of 2.53M shares of common stock for proceeds of $1M; the fund has committed to purchase up to $6M in additional shares of common stock over the next 24 months

7/7/16

Ardelyx Inc. (Fremont, Calif.)

Private placement

12.6S

$110.00

Ardelyx raised $110M by selling 12.6M shares at $8.73 each in a private placement to new and existing investors, including New Enterprise Associates, the firm's largest stockholder, along with Australia's Future Fund, Quadrille Capital, Ecor1 Capital, RA Capital Management, First Manhattan Co., Rock Springs Capital, Cormorant Asset Management, Perceptive Advisors, Deerfield and Dafna Capital Management

7/18/16

Auris Medical Holding AG (Zug, Switzerland)

Loan facility

N/A

$12.50

Auris Medical entered a loan facility agreement with Hercules Capital Inc. for up to $20M in financing; a first tranche of $12.5M has closed

7/21/16

Evoke Pharma Inc. (Solana Beach, Calif.)

Registered direct offering

1.8S

$4.50

Evoke Pharma entered definitive agreements with institutional investors for a registered direct offering of shares of common stock with gross proceeds of approximately $4.5M; it will issue approximately 1.8M registered shares of common stock at $2.49375 per share; concurrently in a private placement, for each share of common stock purchased the investor will receive an unregistered warrant to purchase three-quarters of a share of common stock; the warrants have an exercise price of $2.41 per share

7/21/16

Galena Biopharma Inc. (San Ramon, Calif.)

Registered direct offering

28S

$12.60

Galena Biopharma entered securities purchase agreements with certain institutional investors providing for the issuance of 28M shares of common stock at a purchase price per share of 45 cents each in a registered direct offering, and warrants to purchase up to 14M shares with an exercise price of 65 cents per share in a concurrent private placement, resulting in gross proceeds to the company of $12.6M; Raymond James & Associates Inc. acted as the exclusive placement agent for the offering

7/12/16

Ignyta Inc. (San Diego)

Term loan facility

N/A

N/A

Ignyta secured a $42M term loan facility from Silicon Valley Bank and Oxford Finance, receiving initial funding of $32M, substantially all of which was used to repay the company's prior loan with Silicon Valley Bank, and it has a conditional option to receive an additional $10M

7/5/16

Immuron Ltd. (Melbourne, Australia)

Private placement

24S

$4.51

Immuron said its $6M rights offer for up to 24M shares at 25 cents apiece was 75% subscribed by existing shareholders, generating proceeds of $4.51M

7/8/16

Innovus Pharmaceuticals Inc. (San Diego)

Private placement

Notes

$2.25

Innovus closed a $0.75M convertible promissory note investment from institutional investors for a total of $2.25M; Rodman & Renshaw acted as placement agent

7/19/16

Lattice Biologics Ltd. (Scottsdale, Ariz.)

Private placement of units

1.68U

$0.26

Lattice Biologics closed the first tranche of the partially brokered private placement of units of the company disclosed June 28; the company issued about 1.68M units at a price of 15 cents each, for proceeds of $260,000

7/5/16

Northwest Biotherapeutics Inc. (Bethesda, Md.)

Registered direct offering

7.4S

$3.70

Northwest Biotherapeutics entered definitive agreements with two new institutional investors for a registered direct offering selling about 7.4M shares of common stock at 50 cents each for gross proceeds of $3.7M; the investors will also receive warrants to purchase up to about 3.7M shares of common stock with an exercise price of 60 cents per share

7/6/16

Oragenics Inc. (Tampa, Fla.)

Private placement

9S

$4.60

Oragenics closed a private placement of about 9M shares of common stock to three accredited investors, raising gross proceeds of about $4.6M, of which $2M is payable by the Koski Family LP on Sept. 30, 2016; the purchase price per share was about 51 cents

7/5/16

Poxel SA (Lyon, France)

Private placement

3.4S

$25.50

Poxel closed a capital increase of 3.4M new ordinary shares without preferential subscription rights reserved for a category of investors for a total amount of €26.5M

7/19/16

Propanc Health Group Corp. (Melbourne, Australia)

Private placement

N/A

$0.31

Propanc Health Group executed an agreement with an institutional investor resulting in them receiving $314,286

7/7/16

Stellar Biotechnologies Inc. (Port Hueneme, Calif.)

Registered direct offering

1.68S and W for 1.26S

$6.72

Stellar Biotechnologies entered definitive agreements to sell 1.68M common shares in a registered direct offering and unregistered warrants at $4, raising $6.72M

7/1/16

Sygnis AG (Heidelberg, Germany)

Private placement

20.5S

$22.70

Sygnis completed its rights offering and a subsequent private placement, raising $22.7M through the issue of 20.5M shares

7/19/16

Valneva SE (Lyon, France)

Loan

N/A

$27.60

Valneva said the European Investment Bank granted a €25M (US$27.6M) loan facility

7/13/16


Notes

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed.

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

N/A = Not applicable; ND = Not disclosed.

This chart includes only biotech companies that develop therapeutics.